We read with great interest the recent article by Reddy et al. 1 reporting two cases of CMV encephalitis and reviewing literature, in which it was underlined that this is a problematic infectious complication, often considered to be rare in patients undergoing allogeneic hematopoietic SCT. Indeed, as reported in the article, only few cases have been reported in SCT recipients. 1 We fully agree with the conclusions of the authors on the need to keep in mind the possibility of this neurological infectious complication in SCT patients who manifest clinical symptoms consistent with encephalitis.
In the past 2 months, even at our center, we diagnosed two cases of CMV encephalitis (patients 1 and 2) that occurred in patients undergoing reduced-intensity conditioning transplantation (RIC-SCT). The underlying disease and encephalitis clinical findings are shown in Table 1 . Both cases were HIV negative but their CD4 counts were lower than 100 cells per mm 3 . The diagnosis of CMV encephalitis was carried out by detection of CMV-DNA in cerebrospinal fluid (CSF) using a quantitative PCR method. 2 To confirm the diagnosis, we performed the CSF analysis, for both the cases, in two different laboratories. After diagnosis, the value of viral load in CSF was monitored every 2 weeks during therapy ( Table 1) .
None of the two patients had retinitis but both, before the onset of encephalitis, experienced repeated infectious reactivation of CMV and patient 1 also experienced a CMV pneumonia 1 month after RIC-SCT. Magnetic resonance imaging showed, in both cases, a diffuse increase of signal flair, without other brain abnormalities.
In our patients, the course of this neurological complication was unfavorable, despite a prolonged combination therapy with ganciclovir and Foscavir associated with specific anti-CMV immunoglobulins. [1] [2] [3] The clinical outcome was related with viral load in CSF only in patient 1. Instead, in patient 2, despite a decrease in CSF viral load, there was a progressive neurological deterioration.
In accord with Reddy et al., we think that this severe neurological infectious complication could be more common than previously suspected and it would be important, when SCT recipients show persistent and/or progressive neurological symptoms, to consider this disease and perform a targeted CSF study (by CMV-DNA-specific PCR assay).
1,2
Some conclusive considerations need to be reported: (a) We confirm the late onset of this infectious complication after SCT and its unfavorable outcome, probably due to a partial penetration of antiviral drugs (ganciclovir and Foscavir) into CSF. 4 As a consequence, the response to pharmacological therapy of CMV encephalitis is limited. Table 1 Underling hematological disease and CMV encephalitis clinical findings Ganciclovir plus Foscavir plus specific immunoglobulins Ganciclovir plus Foscavir plus immunoglobulins CMV-DNA copies in CSF during therapy 13 541 copies per mL (after 2 weeks) 54 021 copies per mL (after 4 weeks) 255 000 copies per mL (after 8 weeks) 1 700 000 copies per mL (after 2 weeks) 1 295 760 copies per mL (after 4 weeks) 256 000 copies per mL (after 8 weeks) Outcome Death, 2 months from diagnosis Alive, 2 months from diagnosis with progressive neurological deterioration (b) Our patients had severe and long-lasting immune deficiency with CD4 þ lymphocyte counts lower than 100 cells per mm 3 and received several lines of immunosuppressive therapy. Therefore, in the absence of immunological recovery, the cure of this complication is difficult, despite appropriate anti-CMV-specific therapy. 1, 3 Our observation, along with that reported by Reddy et al., strongly suggests that the diagnosis of CMV encephalitis should be considered and excluded in all SCT patients with severe immunosuppression (CD4 þ counts lower than 100 cells per mm 3 ) who develop rapid and progressive brain dysfunction.
